Merck continued to execute its research and development focused-strategy, advance its pipeline and commercial portfolio while maintaining a disciplined approach to cost management and delivering capital returns to shareholders; the company received several product approvals in 2015 … and in January 2016, the FDA approved Zepatier …; business development is a critical part of the company’s strategy as Merck looks to combine internal and external innovation to enhance its pipeline; while the company continues to execute its strategy of pursuing business development opportunities to complement its internal research capabilities, as part of Merck’s prioritization efforts, the company also continues to review its existing assets to determine whether they can provide the best short- and longer-term value with Merck or elsewhere; in connection with its portfolio assessment process, the company divested its remaining ophthalmics business in international markets during 2015; the company’s portfolio assessment process is ongoing and future divestitures may occur; Merck is focusing its research efforts on the therapeutic areas that it believes can make the most impact on addressing critical areas of unmet medical need; operating conditions have become more challenging under the global pressures of competition, industry regulation and cost containment efforts; although no one can predict the effect of these and other factors on the company’s business, the company continually takes measures to evaluate, adapt and improve the organization and its business practices to better meet customer needs and believes that it is well positioned to respond to the evolving health care environment and market forces; in 2013, the company initiated actions under a global restructuring program … as part of a global initiative to sharpen its commercial and research and development focus; the actions under this program primarily include the elimination of positions in sales, administrative and headquarters organizations, as well as research and development, the reduction of the company’s global real estate footprint and improvements in the efficiency of its manufacturing and supply network; the company recorded total pretax costs of $527 million in 2015 and $1.2 billion in both 2014 and 2013 related to this restructuring program; the actions under the 2013 restructuring program were substantially completed by the end of 2015 and the company has met its projected $2.0 billion in annual net cost savings for actions under the 2013 restructuring program; when the actions under the 2013 restructuring program are combined with the actions under the merger restructuring program, the company has also met its annual net cost savings projection of $2.5 billion compared with full-year 2012 expense levels; the global restructuring program that was initiated in 2010 … is intended to streamline the cost structure of the combined company; the actions under this plan include the elimination of positions in sales, administrative and headquarters organizations, the sale or closure of certain manufacturing and research and development sites and the consolidation of office facilities; the company recorded total pretax costs of $583 million in 2015, $730 million in 2014 and $1.1 billion in 2013 related to this restructuring program; costs associated with the company’s restructuring actions are included in materials and production costs, marketing and administrative expenses, research and development expenses and restructuring costs; the company estimates that approximately two-thirds of the cumulative pretax costs relate to cash outlays, primarily related to employee separation expense, and approximately one-third of the cumulative pretax costs are non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested; Merck continues to support its in-line portfolio, as well as ongoing and upcoming product launches; Merck continues to make strong progress in 2015 reducing its cost base; as a result of disciplined cost management, Merck has achieved its overall savings goal in 2015 as noted below and has in turn invested its resources to grow its strongest brands and to support the most promising assets in its pipeline; marketing and administrative expenses declined in 2015 as compared with 2014 reflecting in part this continued focus by the company on prioritizing its resources to the highest growth areas; the company also continues to review its existing assets to determine whether they can provide the best short- and longer-term value with Merck or elsewhere; in connection with its portfolio assessment process, the company divested its remaining ophthalmics business in international markets during 2015; the company’s portfolio assessment process is ongoing and future divestitures may occur; the company continues to monitor its legal defense costs and review the adequacy of the associated reserves; Merck’s strong financial profile enables it to fully fund research and development, focus on external alliances, support in-line products and maximize upcoming launches while providing significant cash returns to shareholders; the company places its cash and investments in instruments that meet high credit quality standards … and does not participate in any off-balance sheet arrangements involving unconsolidated subsidiaries that provide financing or potentially expose the company to unrecorded financial obligations; Merck has established revenue hedging, balance sheet risk management, and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign exchange rates; the primary objective of the revenue hedging program is to reduce the potential for longer-term unfavorable changes in foreign exchange rates to decrease the U.S. dollar value of future cash flows derived from foreign currency denominated sales; to achieve this objective, the company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales that are expected to occur over its planning cycle; Merck may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing.